Medical Journals Need Taste Of Their Own Medicine, FDA’s Gottlieb Says
Medical journals need to take measures to expedite providing up-to-date information to physicians, FDA Deputy Commissioner for Scientific & Regulatory Affairs Scott Gottlieb said
You may also be interested in...
Merck's Vioxx VIGOR trial results do not need to be corrected, authors of the study assert in letters to the editors of the New England Journal of Medicine Feb. 22
FDA should publish the names and background information of proposed advisory committee members in advance of scheduled meetings, a New England Journal of Medicine editorial recommends
Medical journal editors will apply a case-by-case analysis in determining whether to publish data from Phase II studies that have not been listed in public clinical trial registries, the International Committee of Medical Journal Editors said as the July 1 deadline for trial registration approaches